Last update 28 Apr 2025

Tixagevimab

Overview

Basic Info

Drug Type
Monoclonal antibody
Synonyms
AZD 8895, AZD-8895, AZD8895
Action
inhibitors
Mechanism
SARS-CoV-2 S protein inhibitors(Coronavirus spike glycoprotein inhibitors)
Active Indication
Inactive Indication-
Originator Organization
Active Organization
Inactive Organization-
Drug Highest PhasePhase 1
First Approval Date-
Regulation-
Login to view timeline

Structure/Sequence

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
COVID-19Phase 1
United States
19 May 2022
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Not Applicable
90
Tixagevimab and Cilgavimab (Evusheld)
mwkgusnysm(ghubefgmtf) = jncldoppou kbwejgfdrg (ogdwbbsxbw )
Positive
05 Jun 2024
(Control group (not treated with EVS))
mwkgusnysm(ghubefgmtf) = vqxitlstvo kbwejgfdrg (ogdwbbsxbw )
Not Applicable
Multiple Sclerosis
anti-CD20 monoclonal antibodies
-
nzeejrtyrt(wpmrmngyzv) = Solely four patients (2.08%) developed SARS-CoV-2 infection after Evusheld treatment, presenting with a mild (75%) or moderate (25%) illness. No medical admission was recorded. sywxdrmrtu (wcnpeqodqo )
Positive
30 Sep 2023
Not Applicable
21
Tixagevimab and Cilgavimab (TGM/CGM)
qzxalwhlch(xyotnvtabh) = no COVID-19 related symptoms were observed in the month of follow-up after TGM/CGM administration gbenauokih (ckvsuzodgo )
-
31 May 2023
Not Applicable
-
ptyvgvrihu(zlcwquvolx) = All patients had grade 1 or 2 (mild) severity of COVID-19 lfysbfhjhd (meekubsrph )
Positive
30 May 2023
Not Applicable
55
fcwrhflssm(kytlgbchnp) = all were prescribed oral antivirals zaokcsdhox (vjdwffjkod )
Positive
01 Feb 2023
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free